The study by Emmink, et al. suggests that suppressing GPX2 in cancers with high expression (>820 TPM; based on HT29; the levels in the CRC-derived organoids used were not provided with the default from databases being high expression) might suppress growth and metastatic potential [56]. The gene discussed is GPX2; the disease is colorectal carcinoma.